Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ipecacuanha
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · 1914–2026
Showing the 50 most relevant studies, sorted by most relevant.
du Sert NP, Holmes AM, Wallis R, et al.
2012
- Dogs
- Ferrets
- Rats
Background and purposeEmesis is a multi-system reflex, which is usually investigated using in vivo models. The aim of the study is to compare the response induced by emetic compounds across species and investigate whether dogs, ferrets and rats are all similarly predictive of humans.Experimental approachA systematic review was carried out and relevant publications were identified from PubMed. The search was restricted to four species (human, dog, ferret, rat) and ten compounds representative of various mechanisms of emesis induction (apomorphine, cisplatin, cholecystokinin octapeptide, copper sulphate, cyclophosphamide, ipecacuanha, lithium chloride, morphine, nicotine, rolipram).Key results1046 publications were reviewed, and 311 were included, the main reason for exclusion was the lack of quantitative data. Emetic or pica data were extracted as incidence, intensity or latency. All three animal species identified emetic liability but interspecies differences for dose sensitivity were detected.Conclusions and implicationThese results suggest that emetic liability can be reliably identified in a common laboratory species such as the rat. However, to evaluate the characteristics of the emetic response, no animal species is a universal predictor of emetic liability and the choice of species should be an informed decision based on the type of compound investigated. Limitations relating to the conduct and reporting of emesis studies were identified, the main ones being the lack of comparable outcome measures between human and animal data, and the limited availability of human data in the public domain.
Abstract licence: Public domain
S. Mondal, S. Moktan
Indian Journal of Pharmaceutical Education and Research, 2020
Colinas M, Morweiser C, Dittberner O, et al.
2025
- Alkaloids
- Phylogeny
- Stereoisomerism
Ipecac alkaloids are medicinal monoterpenoid-derived tetrahydroisoquinoline alkaloids found in two distantly related plants: Carapichea ipecacuanha (Gentianales) and Alangium salviifolium (Cornales). Here we provide evidence suggesting that both plants initiate ipecac alkaloid biosynthesis through a nonenzymatic Pictet-Spengler reaction and we elucidate the biosynthetic fate of both the 1R and 1S stereoisomers that are produced in this nonstereoselective reaction. Although the biosynthesis of the 1S-derived protoemetine proceeds according to the same chemical logic in both species, each plant uses a distinct monoterpene precursor. Phylogenetic analyses show examples of independent pathway evolution through parallel and convergently evolved enzymes. This work provides insight into how nature can capitalize on highly reactive starting substrates and the manner in which multistep pathways can arise and lays the foundation for metabolic engineering of these important medicinal compounds.
Abstract licence: CC BY
Julia List, Jasmin Gattringer, Sophie Huszarek, et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
- Killer Cells, Natural
- Cyclotides
- Cell Line, Tumor
Cristina Moll Hüther, V. F. Ferreira, Fernando de Carvalho da Silva, et al.
Natural Product Research, 2023
- Emetine
- Chlorophyll
- Sunlight
Okazaki K, Katano W, Shibata K, et al.
2025
- Plant Shoots
- Plant Growth Regulators
- Cytokinins
In many plant species, the application of exogenous phytohormones is crucial for initiating de novo shoot regeneration. However, ipecac [Carapichea ipecacuanha (Brot) L. Andersson] has a unique ability to develop adventitious shoots on the epidermis of internodal segments without phytohormone treatment. This characteristic allows us to evaluate the effects of endogenous phytohormones in this species. Here, we showed that the presence of the pith, including vascular bundles in the internodal segment, is required to activate both endogenous cytokinin (CK) biosynthesis and adventitious shoot formation. Adventitious shoots were mainly formed in the apical region of internodal segments, where the CK biosynthesis genes ISOPENTENYL TRANSFERASE 3 (CiIPT3) and LONELY GUY 7 (CiLOG7) were spontaneously upregulated in the early culture stage on phytohormone-free medium. In addition, CiIPT3 and CiLOG7 were respectively expressed in the pith and the epidermis of the internodal segments. The expression of CiLOG7 was localized as several spots on the epidermis. These findings suggest that CK precursors are generated in the pith, transferred to the epidermis, and then converted into active CKs, facilitating adventitious shoot formation on the epidermis. Conversely, auxin levels rapidly decreased during culture and remained low in the region of shoot formation. Auxin is transferred to the basal region of internodal segments, and strongly suppressed the CiLOG7 expression and decreased the CK levels. Thus, we conclude that the ectopic expression of CiLOG7 in the epidermis of internodal segments contributes to de novo shoot regeneration in ipecac.
Abstract licence: CC BY
Ana Aparecida Bandini Rossi, Elisa Dos Santos Cardoso, Auana Vicente Tiago, et al.
Revista Brasileira de Plantas Medicinais, 2024
Robson do Santos Alves da Silva, Celice Alexandre Silva, Thadeu Sobral-Souza, et al.
Acta Botânica Brasílica, 2023
Oxford English Dictionary, 2026
Hitarth Mehta, Munjal Thakar
AYUSHDHARA, 2025
Bronchial hyper responsiveness and variable air flow obstruction is the primary causes of episodes of breathlessness, coughing, wheezing, tightness in the chest, among other symptoms of bronchial asthma, a chronic inflammatory disease that may be treated or resolved on its own. When combined with traditional treatments, homeopathic treatment of bronchial asthma shows promise as a supplemental strategy. Although early data points to its possible advantages, more study is required to develop firm clinical recommendations and confirm the efficacy of homeopathic remedies in the management of asthma. An estimated 15–20 million people in India suffer from asthma. About 2% of people in India have it. It contributes to a lower quality of life by limiting physical activity (69%), making it harder to accomplish everyday tasks (85%), and decreasing productivity at work (73%), study (64%), and limits in leisure and lifestyle (78%). Since Homeopathy is founded on the laws of similar, it treats illnesses by using medications that, when administered to healthy people, cause symptoms that are similar. A person is treated holistically with homeopathy. There are medications available to treat acute asthma attacks, stop them from happening again, and address allergens that can cause an asthma attack.
Abstract licence: CC BY-NC-SA 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
82 found
Half-life
20 minutes
Mechanism
The emetic components of ipecac, emetine and cephaeline, act centrally and local…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
10-16 ng/ml
Half-life
20 minutes
Protein binding
Volume of distribution
Metabolism
Elimination
76%
Clearance
75%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L2753]
Reports have suggested that ipecac was vastly used in patients with eating disorders to produce vomiting.[T49]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1113 interactions
[L2753]
The overdose of the components such as emetine is reported to cause the onset of myopathy. Chronic use of this drug has been indicated to produce muscle weakness, waddling gait, dyspnea, left atrial enlargement and reduced left ventricular ejection fraction.[T49]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A33034]
When the patient does not vomit any part of the administered dose, there could be traces in plasma after 24 hours. The component alkaloids are eliminated via the bile and urine as it has been observed a persistence in urine after chronic administration.[T49] Biliary and urinary excretion of ipecac corresponds to 57.5% and 16.5% of the administered dose respectively. From the excreted dose, unchanged cephaeline accountd for 42.4% of the eliminated dose in feces.
[A33036]
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC R05CA04
ATC V03AB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ipecac
Matched from: Ipecacuanha
Additional database identifiers
Drugs Product Database (DPD)
343
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72